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Everything Old Becomes New Again*Vasilis Babaliaros, MD,y Alain Cribier, MDzSEE PAGES 1159 AND 1168T he early animal experiments of transcatheteraortic valve replacement (TAVR) were per-formed by implanting the valve in the Hufna-
gel position (descending aorta just distal to the left
subclavian artery) after the creation of aortic in-
sufﬁciency (AI) created by a bioptome (1). The
absence of calcium in the aortic annulus of sheep,
low coronary arteries, and lack of valve sizing knowl-
edge precluded successful TAVR in the orthotopic
position. Using the Hufnagel position, mid-term
evaluation of transcatheter valves in the systemic
circulation was studied. In contrast to the animal
studies, TAVR in humans with aortic stenosis was
very successful, with appropriate anchoring and
sealing in aortic annuli that were signiﬁcantly less
distensible and calciﬁed.
Since then, multiple other TAVR devices have been
tested in animals and received CE mark approval for
treatment of aortic stenosis. Of note, both the Jena-
Valve (JenaValve Technology, Munich, Germany)
and Symetis ACURATE TA (Symetis, Ecublens,
Switzerland) were approved in Europe in 2011. These
2 valves share several characteristics. They are
deployed transapically (primarily); they are self-
seating; they are anatomically oriented into the
commissures; and they can be deployed in animal
models in the orthotopic position. In fact, the lack of
calcium allows these devices to work more*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
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From the yDivision of Cardiology, Emory University Hospitals, Atlanta,
Georgia; and the zDivision of Cardiology, Charles Nicolle Hospital, Rouen,
France. Dr. Babaliaros is an investigator for Edwards Lifesciences; and is a
consultant for Bard Medical, DirectFlow Medical, and Intervalve. Dr.
Cribier is a consultant for Edwards Lifesciences.effectively. Because of their lower radial force
compared with other TAVR devices and non-
transfemoral delivery systems (up until recently),
both devices have not had a market share in Europe.
However, their design may be ideal to treat AI.
The 2 most common transcatheter valves available
(Edwards Lifesciences, Irvine, California, and Med-
tronic, Minneapolis, Minnesota) have been used to
treat native aortic valve insufﬁciency. Though neither
valve was designed to treat this condition, successful
cases have been reported but required signiﬁcant
oversizing (>20% to 30%) and/or the need for a sec-
ond valve (2). These procedures have been performed
at our centers on a compassionate basis.In this issue of JACC: Cardiovascular Interventions,
single-center experience with the Symetis valve and
multicenter experience with the JenaValve for the
treatment of AI are reported. Wendt et al. (3) describe
an initial experience with the Symetis valve with
100% procedural success and no AI in any patient
except 1 with mild AI at 3 to 6 months follow-up
(n ¼ 8). Additionally, there were no deaths or
strokes in these patients. Seiffert et al. (4) initially
reported on 5 patients with similar results, and now
report on expanded use in multiple centers with the
JenaValve (5). In this larger series of 31 patients, 1
procedure was unsuccessful, requiring a valve-in-
valve procedure; mortality at 30 days was 12.9%,
and mortality at 6 months was 19.3%. One patient had
a progressively worse paravalvular leak that was
thought to be secondary to valve calcification, and
another developed endocarditis at 6 months. Stroke
did not occur.
The good news from these reports is that in
selected patients, acute procedural success for both
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1176devices is very high, and live case demonstrations
performed recently have validated this to the TAVR
community. The JenaValve received CE mark
approval for the treatment of AI in 2013, and we
suspect that Symetis will receive the same approval in
the near future. The not so good news is that TAVR
for AI appears to be a niche market, with only 10% of
valve patients having AI (6), and high-risk/inoperable
patients that would undergo TAVR for AI are even
fewer. What we don’t know is whether these devices
will be durable or feasible in patients with progressive
annulus-root dilation. With a mortality of almost 20%
at 6 months in the JenaValve series, we do not have
any insight into the question. Additionally, do pa-
tients with a history of AI secondary to endocarditis
have a prohibitively high risk of recurrent endo-
carditis after TAVR? This question is also unanswered
and will require signiﬁcantly more than 39 combined
patients from the 2 papers to address.
In the future, devices that are speciﬁcally designed
for the treatment of AI may occupy this space. These
devices may be focused on stabilization of the
annulus-root complex and may be able to treat many
different variations of AI. One such system thathas had success in early human feasibility trials
is the Helio transcatheter aortic dock (Edwards Life-
sciences). The Helio device is a stent frame dipped in
polyethylene terephthalate fabric that captures the
aortic leaﬂets at the aortic root (7). A SAPIEN XT
(Edwards Lifesciences) can then be deployed within
the Helio dock to sandwich the native aortic leaﬂets
in between, sealing and perhaps stabilizing the
annulus. The treatment of AI in patients with an
aneurysmal aorta or aortic dissection deserves very
specialized device development that not only can
stabilize the aortic pathology at the annulus-root
level, but also facilitate treatment of the diseased
ascending and transverse aorta (TAVR with TEVAR
[thoracic endovascular aortic repair] or TAVR-
TEVAR). For now, however, everything old becomes
new again, as we use 2 approved TAVR devices to
treat the new indication of AI.
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